活動日期：113年06月29日(週六)12:30-17:20(含課前及課後測驗時間)   課程直播過程如有異常請及時洽詢台灣乳房醫學會(02-2523-9118；bcst@ms46.hinet.net)
活動地點：線上直播。
主辦單位：台灣乳房醫學會
指導單位：衛生福利部國民健康署
課程表：課程總表；第二場課表
乳e學院介面操作手冊：請點此下載操作手冊

本堂課程認證學分申請中，如以下：
1.台灣乳房醫學會：5分
2.台灣護理學會：(申請中)
3.台灣外科醫學會：(申請中)
4.台灣醫學會：(申請中)
5.台灣專科護理師學會：(申請中)
6.中華民國醫事放射學會：(申請中)
7.中華民國放射線醫學會：(申請中)
8.中華民國癌症醫學會：(申請中)
9.中華民國醫用超音波學會：(申請中)
10.公務人員時數：(申請中)
11.國民健康署疑異(疑陽)時數：4小時
12.國民健康署乳篩時數：2小時 (本系列課程當年度累積上限為3小時，且共計於年底一併上傳時數)

• 備註：
  本乳e學院平台系統中「積分登錄期間」係指學員於該時段完成課程，得獲取時數積分認證資格；「課程開放閱讀期間」係指包含報名、預習、複習等課程開放時段，惟複習等僅作為個人學習，並不包含測驗以及積分認證。
  若欲取得本堂課時數積分，請務必於「積分登錄期間」註記時間內參與並完成課程。

Recent approved premenopausal patient reimbursement in Jan. 2024. Through this program we would like to review the current clinical reference and real world experience of treating  premenopausal patient to provide a clear picture based on reimbursement criteria, clinical reference and treatment experience.

The recent approval of the fixed-dose combination of pertuzumab and trastuzumab (PH FDC SC) for subcutaneous injection provides a more convenient treatment option for HER2-positive breast cancer. This ready-to-use formulation combines two essential HER2-targeted antibodies in one single dose, delivering a proven efficacious regimen without compromising safety or outcomes compared to the standard intravenous preparations. By reducing administration time to just minutes, PH FDC SC maximizes patient comfort and flexibility. This innovative pharmaceutical solution epitomizes the next step forward in improving care delivery for the subset of breast cancer patients who can benefit from dual HER2 blockade. Ultimately, optimizing convenience through developments like PH FDC SC may help to reduce barriers to adherence.

The treatment of HER2-positive metastatic breast cancer (mBC) has advanced significantly in recent decades. Trastuzumab, introduced in 1998, improved survival when added to chemotherapy. Since then, other HER2-targeted agents like pertuzumab, T-DM1, and lapatinib have been approved, further extending progression-free and overall survival. These treatments have given most patients 2-4 years of disease control, but resistance still eventually develops. New strategies aim to prevent or overcome resistance by employing antibody-drug conjugates and combinations to hit multiple targets. The goal is to utilize all effective options in a sequential or combinatorial way until loss of benefit, thereby extending survival as long as possible.

HER2-positive breast cancer has a higher risk of recurrence even after standard chemotherapy and trastuzumab treatment. Neoadjuvant therapy prior to surgery provides benefits like potential downstaging and increased operability. Additionally, achieving pathological complete response (pCR) with neoadjuvant treatment correlates with improved survival. Optimal evaluation and selection of appropriate candidates for neoadjuvant therapy is thus critical. This review examines systemic neoadjuvant and adjuvant treatment strategies for HER2+ breast cancer to help guide clinical decision-making surrounding therapy selection. Key factors are assessing nodal involvement and recurrence risk to determine best approach, considering postsurgical outcomes with each strategy, and utilizing adjuvant T-DM1 if pCR is not achieved with neoadjuvant therapy in the case of residual disease.

This presentation is going to talk about the evolution of combination of target therapy and chemotherapy, standard regimens including anthracycline based, anthracycline-free and Taxane. For low risk patients or patients with comorbidities, how to balance between efficacy and side effect profile?

Last but not least, Dr. Tsai will talk about her insights on cancer treatment without chemotherapy.